UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000028405 |
|---|---|
| Receipt number | R000031915 |
| Scientific Title | Phase 1b investigator initiated trial of combination therapy of Metformin and Nivolumab in participants with advanced or recurrent solid cancer. |
| Date of disclosure of the study information | 2017/07/27 |
| Last modified on | 2023/04/04 09:11:17 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2017/07/27 16:47:25 | ||
| 2 | Update | 2017/08/30 17:13:30 | Recruitment status Anticipated trial start date |
|
| 3 | Update | 2019/06/03 10:14:46 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Address Address Address Address Organization Organization Address Address Tel |
|
| 4 | Update | 2019/06/03 10:18:29 | Date of IRB Last follow-up date |
|
| 5 | Update | 2019/07/09 09:09:47 | Condition |
|
| 6 | Update | 2019/07/09 09:16:23 | Key exclusion criteria |
|
| 7 | Update | 2019/07/09 09:21:15 | Condition |
|
| 8 | Update | 2019/07/09 09:23:05 | Key exclusion criteria |
|
| 9 | Update | 2019/10/29 13:11:07 | Key exclusion criteria Key exclusion criteria |
|
| 10 | Update | 2020/01/28 11:07:57 | Key secondary outcomes Key secondary outcomes |
|
| 11 | Update | 2020/07/28 11:20:44 | Recruitment status |
|
| 12 | Update | 2020/07/28 11:21:35 | Number of participants that the trial has enrolled |
|
| 13 | Update | 2020/10/30 09:02:59 | Last follow-up date |
|
| 14 | Update | 2022/12/02 13:44:03 | Last follow-up date |
|
| 15 | Update | 2023/04/04 09:11:17 | 1st name of lead principal investigator Last name of lead principal investigator Last name of lead principal investigator Division name Division name TEL Institute Department |
